The health-care industry requires large expenditure on research and development (R&D), with many projects undergoing long development cycles, usually with uncertain outcomes. Extant research has mainly concentrated on the health-care industry in the United States, where R&D costs are expensed as...

This article reports the results of a study of the underpricing of initial public offerings under the Corporations Law. The authors commence by outlining a number of theories that have been advanced to explain the persistent underpricing of the issuing company's shares. The authors then examine...

We investigate the value-relevance of capitalised R&D on the balance sheet, and the extent to which R&D accruals improve the association between accounting-based measures of firm performance and capital market returns for Australian listed companies. This is a regulatory setting where management...